Watch KURA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
65
PASS · insiders 78, shorts 51
Insiders, 90 days
+$790K
net buying · 1 buy, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.2BP/E —DIV YIELD —FCF YIELD -9.96%REV TTM $77.2MNET INCOME −$296.8MNET CASH $60.5M52W 7.40 – 13.59SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $20.9M | +36.5% | 98.8% | −$73M | −$68.3M | — | -0.77 | −$62.5M | $656K | −$63.2M | Aug 12 |
| Q1 2026 · Mar 31 | $18.3M | +29.5% | 98.6% | −$78.8M | −$73.3M | — | -0.83 | −$85.9M | $128K | −$86M | Aug 12 |
| Q4 2025 · Dec 31derived | $17.3M | — | — | −$86.3M | −$81M | — | -0.92 | $117.3M | $2.3M | $115M | Mar 5 |
| Q3 2025 · Sep 30 | $20.8M | — | — | −$80M | −$74.1M | — | -0.85 | −$80.6M | $2.6M | −$83.2M | Nov 4 |
| Q2 2025 · Jun 30 | $15.3M | — | — | −$72.7M | −$66.1M | — | -0.75 | −$28.8M | $1.5M | −$30.2M | Aug 12 |
| Q1 2025 · Mar 31 | $14.1M | — | — | −$64.7M | −$57.4M | — | -0.66 | −$71.9M | $292K | −$72.2M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$22.5M | −$19.2M | — | -0.22 | $269.1M | $372K | $268.8M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$59.9M | −$54.4M | — | -0.63 | −$43.4M | $0 | −$43.4M | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | −$56.4M | −$50.8M | — | -0.59 | −$42.5M | $16K | −$42.5M | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$54.5M | −$49.5M | — | -0.59 | −$48.8M | $84K | −$48.9M | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | — | −$42.8M | — | -0.55 | −$34.3M | $16K | −$34.3M | Mar 5 |
| Q3 2023 · Sep 30 | — | — | — | — | −$38.6M | — | -0.50 | −$29M | $20K | −$29M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $67.5M | — | −$303.6M | −$278.7M | -412.9% | -3.18 | −$64.1M | $6.6M | −$70.7M | — | — |
| FY2024 · to Dec 31 | $53.9M | — | −$193.2M | −$174M | -322.9% | -2.02 | $134.3M | $472K | $133.8M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$165.8M | −$152.6M | — | -2.08 | −$124.8M | $168K | −$125M | — | — |
| FY2022 · to Dec 31 | — | — | −$139.9M | −$135.8M | — | -2.03 | −$110.1M | $626K | −$110.7M | — | — |
| FY2021 · to Dec 31 | — | — | — | −$130.5M | — | -1.97 | −$104.6M | $1.1M | −$105.7M | — | — |
| FY2020 · to Dec 31 | — | — | — | −$89.6M | — | -1.69 | −$69.8M | $2.2M | −$72M | — | — |
Every number comes from Kura Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.